Company intelligence / Profile preview

Auven Therapeutics

Saint Thomas, United States Virgin Islands

Ownership: Private
Development stage: Other

Overview

Auven Therapeutics operates as both a private equity firm and an internal drug development company, with several portfolio companies achieving significant milestones. ADC Therapeutics has achieved FDA approval for ZYNLONTA for relapsed or refractory large B-cell lymphoma

Therapeutic areas: OncologyRare DiseasesOphthalmologyWomen's Health
Modalities: Antibody-drug conjugateMonoclonal antibodySmall molecule
Industry: Biotech

Beyond the preview

Go deeper on Auven Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Auven Therapeutics.

Explore the full profile